ArticleClinical and translational medicine2026
Cardiomyocyte-enriched OTUD5 alleviates septic cardiomyopathy by promoting NLRP3 deubiquitination and inhibiting NLRP3 inflammasome activation.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSeptic cardiomyopathy (SCM) is the leading cause of mortality among patients diagnosed with sepsis. Nevertheless, the precise mechanisms underlying its pathogenesis remain poorly understood. Deubiquitinating enzymes (DUBs) play a vital role in various cardiovascular diseases.
methodsThis study investigated deubiquitinating enzymes in septic myocardial injury via public RNA-Seq. Pyroptosis was modelled in primary neonatal rat cardiomyocytes using lipopolysaccharide (LPS) and nigericin, with levels assessed by IL‑1β ELISA, Western blot, PI staining, CCK‑8 and LDH assays. Potential substrates of OTUD5 were screened by Co‑immunoprecipitation. Cardiomyocyte‑specific OTUD5‑knockout mice generated by CRISPR/Cas9 were subjected to LPS‑ or Caecal ligation and puncture (CLP)‑induced sepsis models for cardiac function and pyroptosis evaluation. AAV9‑mediated cardiomyocyte‑specific OTUD5 overexpression in NLRP3‑knockout mice was used to validate OTUD5‑NLRP3 functional interaction.
resultsThis study identifies the deubiquitinating enzyme OTUD5 as being significantly upregulated in myocardial tissue subjected to sepsis induced by LPS and CLP. Cardiomyocyte-specific knockout of OTUD5 leads to exacerbated septic myocardial injury and pyroptosis. Mechanistically, OTUD5 directly interacted with NLRP3, with its C224 site facilitating deubiquitination to inhibit NLRP3 activation. Notably, the protective effects associated with OTUD5 overexpression were lost in NLRP3 knockout mice, underscoring its dependence on NLRP3 for function.
conclusionsThis study has confirmed that OTUD5 inhibits pyroptosis by suppressing the activity of NLRP3, thereby ameliorating septic cardiomyopathy. OTUD5 is worthy of further exploration as a potential therapeutic target for septic cardiomyopathy. KEY POINTS: The expression levels of the deubiquitinating enzyme OTUD5 are elevated in tissues affected by sepsis-induced cardiomyopathy. Cardiomyocyte-specific OTUD5 is a protective factor against myocardial pyroptosis and cardiac dysfunction induced by LPS and CLP. OTUD5 interacts with NLRP3, and its C224 site promotes deubiquitination while inhibiting the activation of NLRP3.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.